Advanced

Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells

Argilés, Josep M; Figueras, Maite; Ametller, Elisabet; Fuster, Gemma; Olivan, Mireia; Fontes Oliveira, Cibely LU ; López-Soriano, Francisco J; Isfort, Robert J and Busquets, Sílvia (2008) In Muscle and Nerve 37(2). p.5-190
Abstract

Previous studies have demonstrated an effect of corticotropin-releasing factor 2 receptor (CRF2R) agonists in the maintenance of skeletal muscle mass. The aim of this study was to evaluate the effects of a CRF2R agonist in preserving skeletal muscle in a mouse cachexia model. Implantation of a fast-growing tumor to mice (Lewis lung carcinoma) resulted in a clear cachectic state characterized by a profound muscle wasting. We found that administration of a CRF2R agonist (PG-873637) at 100 microg/kg/day by means of osmotic minipumps to tumor-bearing mice resulted in beneficial effects on muscle weight loss. Thus, muscle loss was partially reversed by the CRF2R agonist at different stages of tumor growth (at day 14 after tumor inoculation:... (More)

Previous studies have demonstrated an effect of corticotropin-releasing factor 2 receptor (CRF2R) agonists in the maintenance of skeletal muscle mass. The aim of this study was to evaluate the effects of a CRF2R agonist in preserving skeletal muscle in a mouse cachexia model. Implantation of a fast-growing tumor to mice (Lewis lung carcinoma) resulted in a clear cachectic state characterized by a profound muscle wasting. We found that administration of a CRF2R agonist (PG-873637) at 100 microg/kg/day by means of osmotic minipumps to tumor-bearing mice resulted in beneficial effects on muscle weight loss. Thus, muscle loss was partially reversed by the CRF2R agonist at different stages of tumor growth (at day 14 after tumor inoculation: 12% in tibialis posterior; 9% in gastrocnemius; and 48% in soleus). Moreover, the CRF2R agonist significantly reduced both the number of metastases and their mass (at day 19 after tumor inoculation: 66% and 61%, respectively). These data suggest a potentially beneficial effect of the CRF2R agonist in preserving skeletal muscle during cancer cachexia and open a line of research for the development of new therapeutic approaches for the treatment of muscle wasting associated with cancer.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Adipose Tissue, Animals, Cachexia, Carcinoma, Lewis Lung, Corticotropin-Releasing Hormone, Disease Models, Animal, Mice, Mice, Inbred C57BL, Muscle, Skeletal, Neoplasm Transplantation, Organ Size, Receptors, Corticotropin-Releasing Hormone, Statistics, Nonparametric, Time Factors, Journal Article, Research Support, Non-U.S. Gov't
in
Muscle and Nerve
volume
37
issue
2
pages
6 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:38949151848
ISSN
0148-639X
DOI
10.1002/mus.20899
language
English
LU publication?
no
id
d9ae95d5-7f19-44ba-8960-8dc5fa4caeec
date added to LUP
2017-02-28 16:20:44
date last changed
2017-03-05 04:41:26
@article{d9ae95d5-7f19-44ba-8960-8dc5fa4caeec,
  abstract     = {<p>Previous studies have demonstrated an effect of corticotropin-releasing factor 2 receptor (CRF2R) agonists in the maintenance of skeletal muscle mass. The aim of this study was to evaluate the effects of a CRF2R agonist in preserving skeletal muscle in a mouse cachexia model. Implantation of a fast-growing tumor to mice (Lewis lung carcinoma) resulted in a clear cachectic state characterized by a profound muscle wasting. We found that administration of a CRF2R agonist (PG-873637) at 100 microg/kg/day by means of osmotic minipumps to tumor-bearing mice resulted in beneficial effects on muscle weight loss. Thus, muscle loss was partially reversed by the CRF2R agonist at different stages of tumor growth (at day 14 after tumor inoculation: 12% in tibialis posterior; 9% in gastrocnemius; and 48% in soleus). Moreover, the CRF2R agonist significantly reduced both the number of metastases and their mass (at day 19 after tumor inoculation: 66% and 61%, respectively). These data suggest a potentially beneficial effect of the CRF2R agonist in preserving skeletal muscle during cancer cachexia and open a line of research for the development of new therapeutic approaches for the treatment of muscle wasting associated with cancer.</p>},
  author       = {Argilés, Josep M and Figueras, Maite and Ametller, Elisabet and Fuster, Gemma and Olivan, Mireia and Fontes Oliveira, Cibely and López-Soriano, Francisco J and Isfort, Robert J and Busquets, Sílvia},
  issn         = {0148-639X},
  keyword      = {Adipose Tissue,Animals,Cachexia,Carcinoma, Lewis Lung,Corticotropin-Releasing Hormone,Disease Models, Animal,Mice,Mice, Inbred C57BL,Muscle, Skeletal,Neoplasm Transplantation,Organ Size,Receptors, Corticotropin-Releasing Hormone,Statistics, Nonparametric,Time Factors,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  number       = {2},
  pages        = {5--190},
  publisher    = {John Wiley & Sons},
  series       = {Muscle and Nerve},
  title        = {Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells},
  url          = {http://dx.doi.org/10.1002/mus.20899},
  volume       = {37},
  year         = {2008},
}